After Intra-Cellular Therapies announced it has provided the additional non-clinical toxicology data that the FDA requested, Cantor Fitzgerald analyst Charles Duncan says the "rapid" turnaround bodes well for the December 27 action date. Further, the analyst believes the FDA's current plans to not hold a panel meeting reflects the submission of a "robust" new drug application data package and lack of panel-worthy discussion points. He views view the second half of 2019 and early 2020 as "transformational" for Intra-Cellular and keeps an Overweight rating on the shares with a $27 price target.